Analysis of the financial impact and efficiency of the One Stop Prostate Clinic: A same day prostate cancer diagnostic clinic in the Australian public health system

被引:2
|
作者
Hawks, Cynthia [1 ]
Al-Zubaidi, Mohammed [1 ,3 ]
Viswambaram, Pravin [1 ]
Gonsalves, Jude [1 ]
Brown, Matthew [1 ]
Byrnes, Joshua [2 ]
Hayne, Dickon [1 ]
机构
[1] Fiona Stanley Hosp, Murdoch, WA, Australia
[2] Griffith Univ, Nathan, Qld, Australia
[3] Fiona Stanley Hosp, 11 Robin Warren Dr, Murdoch, WA 6150, Australia
关键词
Prostate cancer; public health; One Stop Prostate Clinic; urology; cost minimisation; ACCESS;
D O I
10.1177/22799036221146882
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background:Access to prostate cancer diagnostic clinics are challenging for rural men in Western Australia due to remoteness and long travel distances. The One Stop Prostate Clinic (OSPC) provided same day assessment and diagnosis for prostate cancer in a public tertiary hospital to reduce access barriers for rural men. The objective of this study was to determine the financial and resource utilisation impact of the OSPC compared to a usual care pathway (UCP). Design and methods:Study design: Cost minimisation analysis of the OSPC model (assuming 100% new referrals) compared with a UCP, including impact on the Patient Assisted Transport Scheme (PATS) for rural men. An estimate of total cost comparison of OSPC and UCP pathways of outpatient and diagnostic costs was calculated based on journey mapping of attendance and follow up. Methods:Prospective data collection between August 2011 and November 2017 of referral, attendance and follow up outcomes. Journey mapping to identify time from referral to diagnosis, number of outpatient appointment (OPA) and travel savings. Results:A total of 1000 men attended - 466 (47%) rural and 534 (53%) metro. Mean time from referral to diagnosis was 57 days (rural) versus 63 (metro; p = 0.034)). The OSPC saved 543 travel episodes (distance of 1.5M km) and 658 OPA's. Total episode of care costs for the OSPC (100% new) pathway estimated as $2237.34, compared to $2847.00 for a UCP, generating savings of $609.66 per attendance ($609,658.22 overall). Conclusion:The OSPC was more cost effective and efficient in comparison to a UCP.
引用
收藏
页数:8
相关论文
共 37 条
  • [31] BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
    Gay, J. G.
    Schultz, N. M.
    Braun, S.
    VALUE IN HEALTH, 2018, 21 : S21 - S21
  • [32] Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis
    Cirulli, Giuseppe Ottone
    Davis, Matthew
    Stephens, Alex
    Chiarelli, Giuseppe
    Finati, Marco
    Corsi, Nicholas
    Williams, Eric
    Affas, Rafe
    Sood, Akshay
    Buffi, Nicolo
    Lughezzani, Giovanni
    Carrieri, Giuseppe
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Rogers, Craig
    Abdollah, Firas
    JOURNAL OF UROLOGY, 2024, 212 (04): : 560 - 570
  • [33] DIFFERENTIAL IMPACT OF PROSTATE-SPECIFIC ANTIGEN SCREENING PATTERN ON PROSTATE CANCER-MORTALITY AMONG NON-HISPANIC BLACK AND NON-HISPANIC WHITE MEN: A LARGE, URBAN HEALTH SYSTEM COHORT ANALYSIS
    Cirulli, Giuseppe O.
    Matthew, Davis
    Stephens, Alex
    Chiarelli, Giuseppe
    Finati, Marco
    Corsi, Nicholas
    Williams, Eric
    Affas, Rafe
    Sood, Akshay
    Buffi, Nicolo
    Lughezzani, Giovanni
    Carrieri, Giuseppe
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Rogers, Craig
    Abdollah, Firas
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1056 - E1057
  • [34] Differential impact of prostate-specific antigen screening pattern on prostate cancer-mortality among non-Hispanic black and non-Hispanic white men: A large, urban health system cohort analysis
    Cirulli, G. O.
    Davis, M.
    Finati, M.
    Chiarelli, G.
    Stephens, A.
    Corsi, N.
    Williams, E.
    Affas, R.
    Arora, S.
    Sood, A.
    Lughezzani, G.
    Buffi, N.
    Carrieri, G.
    Salonia, A.
    Briganti, A.
    Montorsi, F.
    Rogers, C.
    Abdollah, F.
    EUROPEAN UROLOGY, 2024, 85 : S404 - S405
  • [35] REMOVAL OF THE FINANCIAL BARRIER TO HEALTH-CARE - DOES IT IMPACT ON PROSTATE-CANCER AT PRESENTATION AND SURVIVAL - A COMPARATIVE-STUDY BETWEEN BLACK-AND-WHITE MEN IN A VETERANS AFFAIRS SYSTEM
    POWELL, IJ
    SCHWARTZ, K
    HUSSAIN, M
    UROLOGY, 1995, 46 (06) : 825 - 830
  • [36] BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS AFTER DOCETAXEL FAILURE IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
    Asano, E.
    Vitale, V.
    VALUE IN HEALTH, 2014, 17 (07) : A622 - A622
  • [37] BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Vitale, V.
    Asano, E.
    Pereira, M. L.
    VALUE IN HEALTH, 2013, 16 (07) : A665 - A665